Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential cisplatin + gemcitabine followed by docetaxel in elderly advanced NSCLC
2008-005294-35Phase 2Active
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- Jan 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, gemcitabine and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Azienda USL Toscana Nord Ovest. Primary endpoint: progression rate at 4 months. Started Jan 2009; status: active.
02
Drugs
cisplatingemcitabinedocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-005294-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005294-35.